Arvinas is a clinical-stage biotechnology company committed to enhancing patient outcomes through the discovery, development, and commercialization of novel therapies designed to degrade disease-causing proteins. Utilizing its proprietary PROTAC Discovery Engine, Arvinas engineers targeted protein degraders that enter the body's natural protein disposal pathways, offering new treatment possibilities for conditions like cancer and neurodegenerative diseases. The company is advancing several investigational drugs through clinical development, including treatments for breast cancer, prostate cancer, and various lymphomas. Arvinas prides itself on having a diverse and collaborative workforce of approximately 450 employees who are encouraged to innovate and contribute to its mission of pioneering advanced therapeutic solutions for serious diseases. Emphasizing integrity, creativity, and community engagement, Arvinas offers a dynamic environment for those looking to make a tangible impact in the field of biotechnology.